Details

Adalimumab, a TNF-alpha (Tumor Necrosis Factor-Alpha), blocker is indicated for the reduction of inflammation. The drug is prescribed for the treatment of psoriatic arthritis, plaque psoriasis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis. Adalimumab is also prescribed for treatment of Crohn’s disease patients who are unresponsive to treatment procedures.